Literature DB >> 28138114

Disulfiram Induced Psychosis.

Satyakam Mohapatra1, Nihar Ranjan Rath1.   

Abstract

Disulfiram is the commonly prescribed drug for the treatment of alcohol dependence. It's major metabolite (diethyldithiocarbamate) is an inhibitor of dopamine-betahydroxylase, an enzyme that catalyzes the metabolism of dopamine to norepinephrine resulting in psychosis. We recommend that disulfiram should be used at the lowest effective dose, possibly 250 mg daily and caution should be taken while prescribing disulfiram for patients with personal and familial antecedents of psychosis.

Entities:  

Keywords:  Disulfiram; Psychosis; Side effect

Year:  2017        PMID: 28138114      PMCID: PMC5290718          DOI: 10.9758/cpn.2017.15.1.68

Source DB:  PubMed          Journal:  Clin Psychopharmacol Neurosci        ISSN: 1738-1088            Impact factor:   2.582


INTRODUCTION

For the past 50 years disulfiram is the commonly prescribed drug for the treatment of alcohol dependence. Important side effects of disulfiram are hepatological, dermatological, neurological (polyneuritis, encephalopathy)1,2) and psychiatric in nature. Psychiatric manifestations include confusion, loss of memory, psychosis,3–6) mania with psychotic symptoms.7,8) Disulfiram’s major metabolite diethyldithiocarbamate is an inhibitor of dopamine-betahydroxylase (DBH), an enzyme that catalyzes the metabolism of dopamine (DA) to norepinephrine (NE).9) By inhibiting this metabolic pathway from DA to NE in the central nervous system, disulfiram results in an increase of DA concentrations in mesolimbic system resulting in psychosis. Alcoholics who developed psychotic symptoms during disulfiram treatment are found to have low levels of amine and monoamine oxidase, suggesting DBH blockage.10) We present a case of 32-year-old male who developed psychosis with the use of disulfiram.

CASE

A 32-year-old male without past of psychiatric and neurological illness reported to psychiatry outpatient department with complaint of daily alcohol intake of 250–750 ml (40% alcohol by volume) for the last 5 years. With the informed consent of the patient, disulfiram was administered at the dosage of 250 mg twice daily for 1 month, while the patient abstained from alcohol. Then the patient presented complaint of fearfulness, suspiciousness, easy irritability, muttering to self, decreased sleep for last one month. Detailed medical evaluation revealed no significant findings. Haematological and biochemical indices were within normal limits. On mental status examination delusion of persecution and auditory hallucinations were elicited. He has family history of schizophrenia and comorbid alcohol dependence in his father. The patient has no history of any other substance abuse. The patient was hospitalised and possibility of psychosis induced by disulfiram was kept. Disulfiram was stopped. Symptoms of alcohol withdrawal and disulfiram-alcohol reactions were not observed during hospitalization. He was started on tablet lorazepam 4 mg per day. His fearfulness, suspiciousness, irritability, muttering to self and impaired sleep gradually improved over a period of 10 days. After 2 weeks he improved completely and lorazepam was stopped.

DISCUSSION

Risk factors for development of disulfiram related psychotic symptoms include past history or family history of psychosis, overly rapid increase in dosage or greater than recommended total dosage, old age, impaired liver function and concurrent dopaminergic medications or psycho-stimulant abuse.5,11) Our patient has family history of schizophrenia in his father. His psychotic symptoms improved after stoppage of disulfiram and use of lorazepam tablet only without any additional requirement of anti-psychotic treatment. These factors support the association between with disulfiram use and emergence of psychotic symptoms in our patient. The usual recommended initial dosage is 500 mg per day for the first 1 or 2 weeks, followed by a maintenance dosage of 250 mg per day.12) Disulfiram related psychosis usually involve either therapeutic or higher than recommended dosages.13) Our patient has developed psychotic symptoms with 500 mg per day of disulfiram. We recommend that disulfiram should be used at the lowest effective dose, possibly 250 mg daily. Our case highlights the relevance of a careful history of patient’s symptoms and family history that should be performed before starting treatment with disulfiram and caution should be taken while prescribing disulfiram for patients with personal and familial antecedents of psychosis. Disulfiram-related psychiatric complications are reported to be more prevalent in eastern countries,3) which suggests that genetic factors may play a role in disulfiram induced psychosis.
  12 in total

1.  Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram.

Authors:  Mei-Ying Li; Yu-Chih Shen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-29       Impact factor: 5.067

2.  Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report.

Authors:  Mehmet Emin Ceylan; Ahmet Turkcan; Elif Mutlu; Osman Onal
Journal:  J Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.153

3.  L-dopa, dopamine, and hypomania.

Authors:  D L Murphy; F K Goodwin; H K Brodie; W E Bunney
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

4.  Vulnerability to disulfiram psychosis.

Authors:  H A Nasrallah
Journal:  West J Med       Date:  1979-06

5.  Cannabis toxic psychosis while on disulfiram.

Authors:  J Mackie; D Clark
Journal:  Br J Psychiatry       Date:  1994-03       Impact factor: 9.319

6.  How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice.

Authors:  C Brewer
Journal:  Br J Psychiatry       Date:  1984-02       Impact factor: 9.319

7.  Disulfiram psychosis. A case report.

Authors:  M Quail; R H Karelse
Journal:  S Afr Med J       Date:  1980-04-05

8.  Disulfiram-induced encephalopathy.

Authors:  J R Hotson; J W Langston
Journal:  Arch Neurol       Date:  1976-02

Review 9.  Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review.

Authors:  E W Larson; A Olincy; T A Rummans; R M Morse
Journal:  Alcohol Clin Exp Res       Date:  1992-02       Impact factor: 3.455

10.  Disulfiram-induced neuropathy: a case report.

Authors:  Satyakam Mohapatra; Manas Ranjan Sahoo; Neelmadhav Rath
Journal:  Gen Hosp Psychiatry       Date:  2014-10-07       Impact factor: 3.238

View more
  6 in total

Review 1.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

2.  Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.

Authors:  Sven Reinhardt; Nicolai Stoye; Mathias Luderer; Falk Kiefer; Ulrich Schmitt; Klaus Lieb; Kristina Endres
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

3.  Comment on: Disulfiram Induced Psychosis (Mohapatra and Rath, Clin Psychopharmacol Neurosci 2017;15:68-69).

Authors:  Petros N Karamanakos; Eleftheria S Panteli
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-08-31       Impact factor: 2.582

4.  Acute Disulfiram Poisoning in a Child: A Case Report and Review of Literature.

Authors:  Kapil Bhalla; Kundan Mittal; Ashish Gupta; Deepak Nehra
Journal:  Indian J Crit Care Med       Date:  2020-03

Review 5.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

6.  Disulfiram Produces Potent Anxiolytic-Like Effects Without Benzodiazepine Anxiolytics-Related Adverse Effects in Mice.

Authors:  Akiyoshi Saitoh; Yoshifumi Nagayama; Daisuke Yamada; Kosho Makino; Toshinori Yoshioka; Nanami Yamanaka; Momoka Nakatani; Yoshino Takahashi; Mayuna Yamazaki; Chihiro Shigemoto; Misaki Ohashi; Kotaro Okano; Tomoki Omata; Etsuko Toda; Yoshitake Sano; Hideyo Takahashi; Kouji Matsushima; Yuya Terashima
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.